← Dashboard
Stock
ZTS
Zoetis Inc.Health CarePharmaceuticalsLatest close $787 of 27 marquee funds currently hold1 CUSIP mapped
Current holders
7
27 funds tracked
Ever held
12
Current + past
New this quarter
0
Exited this quarter
1
Marquee-fund ownership over time
Nov 14, 2013Feb 14, 2019Feb 13, 2023May 15, 2026
Now
7
This quarter's activity
New positions opened
None.
Positions exited
Current holders
Sorted by tenure (longest first)| Fund | First disclosed | Held | Entry price | Latest close | Return on entry |
|---|---|---|---|---|---|
| Bridgewater Associates re-entered | Q1 2021 | 22Q | $158 | $78 | -51% |
| Citadel Advisors re-entered | Q3 2024(8Q snapshot) | 7Q | $179 | $78 | -57% |
| Two Sigma Investments | Q3 2024(8Q snapshot) | 7Q | $179 | $78 | -57% |
| D.E. Shaw | Q3 2024(8Q snapshot) | 7Q | $179 | $78 | -57% |
| AQR Capital Management | Q3 2024(8Q snapshot) | 7Q | $179 | $78 | -57% |
| Millennium Management | Q3 2024(8Q snapshot) | 7Q | $179 | $78 | -57% |
| Renaissance Technologies | Q3 2025(8Q snapshot) | 3Q | $151 | $78 | -48% |
“Return on entry” is the price-only move from the fund's first disclosure to today — it ignores any adds, trims, or dividends. A fund that built its position over multiple quarters has a true cost basis somewhere between entry price and latest close; this figure is the upper bound.
Past holders
Funds that exited at some point| Fund | Last entry | Exited | Entry → Exit | Return |
|---|---|---|---|---|
| Soros Fund Management | Q1 2026 | Q2 2026 | → $74 | -41% |
| Maverick Capital 6× in & out | Q2 2024 | Q3 2024 | → $179 | +6% |
| JANA Partners 2× in & out | Q4 2018 | Q1 2019 | → $88 | +1% |
| Pershing Square | Q4 2014 | Q1 2017 | → $51 | +30% |
| Duquesne Family Office | Q2 2016 | Q1 2017 | → $51 | +18% |
Insider activity
Form 4 — officers, directors, 10%+ ownersFiled within two business days of each transaction by anyone with material insider status at Zoetis Inc.. Pair with the holders table above as a sanity check: heavy insider buying alongside marquee-fund accumulation is the strongest accumulation signal; heavy insider selling alongside fund exits is the strongest distribution signal.
Filings · last 30d
6
Filings · last 90d
25
Total on file
776
Recent SEC buffer
Most recent
May 26, 2026
30d / 90d windows measured from May 26, 2026 — the most recent Form 4 on file — not from today.
- Form 40001628280-26-038153May 26, 2026
- Form 40001628280-26-037351May 21, 2026
- Form 40001628280-26-034643May 13, 2026
- Form 40001628280-26-034642May 13, 2026
- Form 40001628280-26-034291May 12, 2026
- Form 40001628280-26-029358May 1, 2026
- Form 40001628280-26-024969Apr 13, 2026
- Form 40001628280-26-024968Apr 13, 2026
- Form 40001628280-26-024967Apr 13, 2026
- Form 40001628280-26-024965Apr 13, 2026
- Form 40001628280-26-024964Apr 13, 2026
- Form 40001628280-26-024963Apr 13, 2026
- Form 40001628280-26-024962Apr 13, 2026
- Form 40001628280-26-024961Apr 13, 2026
- Form 40001628280-26-022823Apr 1, 2026
Showing 15 of 776 recent Form 4 filings. Browse all on EDGAR ↗
Fundamentals
XBRL · Zoetis Inc.Annual figures sourced directly from Zoetis Inc.'s 10-K / 10-Q filings via SEC EDGAR XBRL. Latest fiscal year and the year-over-year change, with up to ten years of history.
Revenue
$9.47B
FY2025+2% YoY
Net income
$2.67B
FY2025+8% YoY
EPS (diluted)
$6.02
FY2025+10% YoY
Free cash flow(?)
$2.28B
FY2025-1% YoY
Recent SEC filings
10-K · 10-Q · 8-K · 13D/G · proxyThe most recent material filings for Zoetis Inc. — earnings, material events, ownership disclosures, proxy statements. Form 4 insider activity is shown in the panel above.
- 8-KMaterial eventMay 22, 2026
- 8-KMaterial eventMay 20, 2026
- 10-QQuarterly reportMay 7, 2026
- 8-KMaterial eventMay 7, 2026
- DEF 14AProxy statementApr 8, 2026
- 10-KAnnual reportFeb 12, 2026
- 8-KMaterial eventFeb 12, 2026
- 8-KMaterial eventFeb 5, 2026
- 8-KMaterial eventDec 18, 2025
- 8-KMaterial eventDec 11, 2025
- 8-KMaterial eventDec 2, 2025
- 10-QQuarterly reportNov 4, 2025
- 8-KMaterial eventNov 4, 2025
- 8-KMaterial eventOct 28, 2025
- 8-KMaterial eventOct 9, 2025
Trade history
Every open→close lifecycle across tracked funds| Fund | Open date | Close date | Open price | Close price / current | Return |
|---|---|---|---|---|---|
| Soros Fund Management | Q1 2026 | Q2 2026 | $126 | $74 | -41% |
| Renaissance Technologies | Q3 2025 | open | $151 | $78 | -48% |
| Citadel Advisors | Q1 2025 | open | $155 | $78 | -50% |
| Citadel Advisors | Q3 2024 | Q4 2024 | $179 | $171 | -5% |
| Two Sigma Investments | Q3 2024 | open | $179 | $78 | -57% |
| D.E. Shaw | Q3 2024 | open | $179 | $78 | -57% |
| AQR Capital Management | Q3 2024 | open | $179 | $78 | -57% |
| Millennium Management | Q3 2024 | open | $179 | $78 | -57% |
| Maverick Capital | Q2 2024 | Q3 2024 | $169 | $179 | +6% |
| Maverick Capital | Q4 2023 | Q1 2024 | $167 | $179 | +7% |
| Bridgewater Associates | Q1 2023 | open | $157 | $76 | -51% |
| Bridgewater Associates | Q3 2021 | Q4 2022 | $192 | $137 | -29% |
| Maverick Capital | Q2 2021 | Q3 2022 | $162 | $167 | +3% |
| Bridgewater Associates | Q1 2021 | Q2 2021 | $158 | $164 | +4% |
| Maverick Capital | Q3 2019 | Q1 2020 | $115 | $136 | +19% |
| JANA Partners | Q4 2018 | Q1 2019 | $86 | $88 | +1% |
| Maverick Capital | Q2 2018 | Q2 2019 | $78 | $96 | +23% |
| Duquesne Family Office | Q2 2016 | Q1 2017 | $43 | $51 | +18% |
| JANA Partners | Q4 2015 | Q1 2016 | $42 | $37 | -11% |
| Pershing Square | Q4 2014 | Q1 2017 | $39 | $51 | +30% |
| Maverick Capital | Q4 2013 | Q2 2014 | $29 | $28 | -3% |
Caveats
- Covers only the 27 marquee funds tracked here, not the full institutional universe. A “0 holders” reading does not mean unowned.
- Heavy funds (Renaissance Technologies, Citadel Advisors, Soros Fund Management, Two Sigma Investments, D.E. Shaw, AQR Capital Management, Millennium Management, Point72 Asset Management) use 8-quarter snapshots, so their pre-2024 history is missing.
- “Current” reflects each fund's most recent 13F — filings lag the actual trade by up to 45 days; positions shown may have changed since.
- Cost = price at the entry filing date. Re-entered positions show the most recent open lot.
- Options, ADRs, and unmapped CUSIPs are excluded from the follower-backtest pipeline that produces these snapshots, so certain holding types won't appear here.